questionsmedicales.fr
Facteurs biologiques
Pigments biologiques
Porphyrines
Porphyrines : Questions médicales fréquentes
Termes MeSH sélectionnés :
Structure-Activity Relationship
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Porphyrines : Questions médicales les plus fréquentes",
"headline": "Porphyrines : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Porphyrines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-04",
"dateModified": "2025-02-27",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Porphyrines"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Pigments biologiques",
"url": "https://questionsmedicales.fr/mesh/D010860",
"about": {
"@type": "MedicalCondition",
"name": "Pigments biologiques",
"code": {
"@type": "MedicalCode",
"code": "D010860",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.767"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Coproporphyrines",
"alternateName": "Coproporphyrins",
"url": "https://questionsmedicales.fr/mesh/D003306",
"about": {
"@type": "MedicalCondition",
"name": "Coproporphyrines",
"code": {
"@type": "MedicalCode",
"code": "D003306",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.767.727.250"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Deutéroporphyrines",
"alternateName": "Deuteroporphyrins",
"url": "https://questionsmedicales.fr/mesh/D003905",
"about": {
"@type": "MedicalCondition",
"name": "Deutéroporphyrines",
"code": {
"@type": "MedicalCode",
"code": "D003905",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.767.727.280"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Étioporphyrines",
"alternateName": "Etioporphyrins",
"url": "https://questionsmedicales.fr/mesh/D005044",
"about": {
"@type": "MedicalCondition",
"name": "Étioporphyrines",
"code": {
"@type": "MedicalCode",
"code": "D005044",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.767.727.340"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Hématoporphyrines",
"alternateName": "Hematoporphyrins",
"url": "https://questionsmedicales.fr/mesh/D006415",
"about": {
"@type": "MedicalCondition",
"name": "Hématoporphyrines",
"code": {
"@type": "MedicalCode",
"code": "D006415",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.767.727.462"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Hématoporphyrine D",
"alternateName": "Hematoporphyrin Derivative",
"url": "https://questionsmedicales.fr/mesh/D017324",
"about": {
"@type": "MedicalCondition",
"name": "Hématoporphyrine D",
"code": {
"@type": "MedicalCode",
"code": "D017324",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.767.727.462.400"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Éther de dihématoporphyrine",
"alternateName": "Dihematoporphyrin Ether",
"url": "https://questionsmedicales.fr/mesh/D017323",
"about": {
"@type": "MedicalCondition",
"name": "Éther de dihématoporphyrine",
"code": {
"@type": "MedicalCode",
"code": "D017323",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.767.727.462.400.200"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Éther de dihématoporphyrine",
"alternateName": "Dihematoporphyrin Ether",
"url": "https://questionsmedicales.fr/mesh/D017323",
"about": {
"@type": "MedicalCondition",
"name": "Éther de dihématoporphyrine",
"code": {
"@type": "MedicalCode",
"code": "D017323",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.767.727.462.400.200"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Mésoporphyrines",
"alternateName": "Mesoporphyrins",
"url": "https://questionsmedicales.fr/mesh/D008652",
"about": {
"@type": "MedicalCondition",
"name": "Mésoporphyrines",
"code": {
"@type": "MedicalCode",
"code": "D008652",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.767.727.620"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Métalloporphyrines",
"alternateName": "Metalloporphyrins",
"url": "https://questionsmedicales.fr/mesh/D008665",
"about": {
"@type": "MedicalCondition",
"name": "Métalloporphyrines",
"code": {
"@type": "MedicalCode",
"code": "D008665",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.767.727.640"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Hème",
"alternateName": "Heme",
"url": "https://questionsmedicales.fr/mesh/D006418",
"about": {
"@type": "MedicalCondition",
"name": "Hème",
"code": {
"@type": "MedicalCode",
"code": "D006418",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.767.727.640.587"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Hémine",
"alternateName": "Hemin",
"url": "https://questionsmedicales.fr/mesh/D006427",
"about": {
"@type": "MedicalCondition",
"name": "Hémine",
"code": {
"@type": "MedicalCode",
"code": "D006427",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.767.727.640.587.462"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Hémine",
"alternateName": "Hemin",
"url": "https://questionsmedicales.fr/mesh/D006427",
"about": {
"@type": "MedicalCondition",
"name": "Hémine",
"code": {
"@type": "MedicalCode",
"code": "D006427",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.767.727.640.587.462"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Protoporphyrines",
"alternateName": "Protoporphyrins",
"url": "https://questionsmedicales.fr/mesh/D011524",
"about": {
"@type": "MedicalCondition",
"name": "Protoporphyrines",
"code": {
"@type": "MedicalCode",
"code": "D011524",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.767.727.725"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Uroporphyrines",
"alternateName": "Uroporphyrins",
"url": "https://questionsmedicales.fr/mesh/D014578",
"about": {
"@type": "MedicalCondition",
"name": "Uroporphyrines",
"code": {
"@type": "MedicalCode",
"code": "D014578",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.767.727.880"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Porphyrines",
"alternateName": "Porphyrins",
"code": {
"@type": "MedicalCode",
"code": "D011166",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Harry L Anderson",
"url": "https://questionsmedicales.fr/author/Harry%20L%20Anderson",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, University of Oxford, Chemistry Research Laboratory, OX1 3TA, Oxford, UK."
}
},
{
"@type": "Person",
"name": "Donato Monti",
"url": "https://questionsmedicales.fr/author/Donato%20Monti",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, Sapienza, University of Rome Piazzale Aldo Moro 5 00185 Rome Italy."
}
},
{
"@type": "Person",
"name": "Manuela Stefanelli",
"url": "https://questionsmedicales.fr/author/Manuela%20Stefanelli",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemical Science and Technologies, University of Rome Tor Vergata via della Ricerca Scientifica 1 00133 Rome Italy gabriele.magna@uniroma2.it."
}
},
{
"@type": "Person",
"name": "Gabriele Magna",
"url": "https://questionsmedicales.fr/author/Gabriele%20Magna",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemical Science and Technologies, University of Rome Tor Vergata via della Ricerca Scientifica 1 00133 Rome Italy gabriele.magna@uniroma2.it."
}
},
{
"@type": "Person",
"name": "Roberto Paolesse",
"url": "https://questionsmedicales.fr/author/Roberto%20Paolesse",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemical Science and Technologies, University of Rome Tor Vergata via della Ricerca Scientifica 1 00133 Rome Italy gabriele.magna@uniroma2.it."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Relationship between Oral Health and Glaucoma Traits in the United Kingdom.",
"datePublished": "2024-03-05",
"url": "https://questionsmedicales.fr/article/38506820",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/IJG.0000000000002370"
}
},
{
"@type": "ScholarlyArticle",
"name": "The untapped potential of cell culture in disentangling insect-microbial relationships.",
"datePublished": "2024-02-29",
"url": "https://questionsmedicales.fr/article/38841412",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.20517/mrr.2023.66"
}
},
{
"@type": "ScholarlyArticle",
"name": "The relationship between political ideology and judgements of bias in distributional outcomes.",
"datePublished": "2024-02-26",
"url": "https://questionsmedicales.fr/article/38409287",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41562-023-01779-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "Dose-effect relationships in neuroendocrine tumour liver metastases treated with [",
"datePublished": "2024-02-19",
"url": "https://questionsmedicales.fr/article/38369678",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00259-024-06645-6"
}
},
{
"@type": "ScholarlyArticle",
"name": "Superconductivity-Electron Count Relationship in Heusler Phases-the Case of LiPd",
"datePublished": "2024-02-15",
"url": "https://questionsmedicales.fr/article/38435048",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acs.chemmater.3c02398"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Pigments biologiques",
"item": "https://questionsmedicales.fr/mesh/D010860"
},
{
"@type": "ListItem",
"position": 4,
"name": "Porphyrines",
"item": "https://questionsmedicales.fr/mesh/D011166"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Porphyrines - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Porphyrines",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-12",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Porphyrines",
"description": "Comment diagnostiquer une porphyrie ?\nQuels tests sont utilisés pour les porphyrines ?\nQuels symptômes indiquent une porphyrie ?\nLes tests génétiques sont-ils nécessaires ?\nComment interpréter les résultats des tests ?",
"url": "https://questionsmedicales.fr/mesh/D011166?mesh_terms=Structure-Activity+Relationship&page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Porphyrines",
"description": "Quels sont les symptômes courants des porphyries ?\nLes porphyries causent-elles des douleurs ?\nY a-t-il des symptômes cutanés ?\nLes porphyries affectent-elles le système nerveux ?\nLes symptômes varient-ils selon le type de porphyrie ?",
"url": "https://questionsmedicales.fr/mesh/D011166?mesh_terms=Structure-Activity+Relationship&page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Porphyrines",
"description": "Comment prévenir les crises de porphyrie ?\nY a-t-il des conseils diététiques pour les patients ?\nLes patients doivent-ils éviter certains médicaments ?\nLa gestion du stress est-elle importante ?\nLes patients doivent-ils être suivis régulièrement ?",
"url": "https://questionsmedicales.fr/mesh/D011166?mesh_terms=Structure-Activity+Relationship&page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Porphyrines",
"description": "Quel est le traitement principal des porphyries ?\nLes transfusions sanguines sont-elles nécessaires ?\nY a-t-il des médicaments spécifiques pour les porphyries ?\nComment gérer les crises de porphyrie ?\nLa photoprotection est-elle recommandée ?",
"url": "https://questionsmedicales.fr/mesh/D011166?mesh_terms=Structure-Activity+Relationship&page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Porphyrines",
"description": "Quelles sont les complications possibles des porphyries ?\nLes porphyries peuvent-elles causer des dommages au foie ?\nY a-t-il un risque accru de cancer ?\nLes complications neurologiques sont-elles fréquentes ?\nComment gérer les complications des porphyries ?",
"url": "https://questionsmedicales.fr/mesh/D011166?mesh_terms=Structure-Activity+Relationship&page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Porphyrines",
"description": "Quels sont les facteurs de risque des porphyries ?\nL'hérédité joue-t-elle un rôle ?\nLes femmes sont-elles plus à risque ?\nL'alcool augmente-t-il le risque ?\nLes infections peuvent-elles aggraver la condition ?",
"url": "https://questionsmedicales.fr/mesh/D011166?mesh_terms=Structure-Activity+Relationship&page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une porphyrie ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests sanguins et urinaires pour mesurer les niveaux de porphyrines."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour les porphyrines ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent l'analyse des urines, du sang et parfois des biopsies de peau."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une porphyrie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure des douleurs abdominales, des troubles neurologiques et des photosensibilités."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils nécessaires ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests génétiques peuvent aider à confirmer certains types de porphyries héréditaires."
}
},
{
"@type": "Question",
"name": "Comment interpréter les résultats des tests ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés de porphyrines dans le sang ou l'urine indiquent une porphyrie."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants des porphyries ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des douleurs abdominales, des éruptions cutanées et des troubles mentaux."
}
},
{
"@type": "Question",
"name": "Les porphyries causent-elles des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs abdominales aiguës sont fréquentes lors des crises de porphyrie."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes cutanés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des éruptions cutanées et une photosensibilité peuvent survenir, surtout dans la porphyrie cutanée."
}
},
{
"@type": "Question",
"name": "Les porphyries affectent-elles le système nerveux ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent provoquer des troubles neurologiques, y compris des crises et des hallucinations."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type de porphyrie ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, chaque type de porphyrie présente des symptômes spécifiques et des manifestations cliniques."
}
},
{
"@type": "Question",
"name": "Comment prévenir les crises de porphyrie ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les déclencheurs comme certains médicaments, l'alcool et le stress peut aider."
}
},
{
"@type": "Question",
"name": "Y a-t-il des conseils diététiques pour les patients ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et riche en glucides peut aider à prévenir les crises."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils éviter certains médicaments ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent déclencher des crises et doivent être évités."
}
},
{
"@type": "Question",
"name": "La gestion du stress est-elle importante ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la gestion du stress est cruciale pour prévenir les crises de porphyrie."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils être suivis régulièrement ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi médical régulier est essentiel pour surveiller l'évolution de la maladie."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal des porphyries ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement principal inclut l'évitement des déclencheurs et des médicaments pour soulager les symptômes."
}
},
{
"@type": "Question",
"name": "Les transfusions sanguines sont-elles nécessaires ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Dans certains cas, des transfusions peuvent être nécessaires pour traiter l'anémie associée."
}
},
{
"@type": "Question",
"name": "Y a-t-il des médicaments spécifiques pour les porphyries ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme l'hématine peuvent être utilisés pour traiter les crises aiguës de porphyrie."
}
},
{
"@type": "Question",
"name": "Comment gérer les crises de porphyrie ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les crises peuvent être gérées par des soins d'urgence et des traitements symptomatiques."
}
},
{
"@type": "Question",
"name": "La photoprotection est-elle recommandée ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients doivent éviter l'exposition au soleil et utiliser des écrans solaires."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles des porphyries ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des lésions nerveuses, des problèmes hépatiques et des infections."
}
},
{
"@type": "Question",
"name": "Les porphyries peuvent-elles causer des dommages au foie ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines porphyries peuvent entraîner des lésions hépatiques graves."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de cancer ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines porphyries, comme la porphyrie cutanée, peuvent augmenter le risque de cancer de la peau."
}
},
{
"@type": "Question",
"name": "Les complications neurologiques sont-elles fréquentes ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications neurologiques peuvent survenir, affectant la qualité de vie."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications des porphyries ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des complications nécessite un suivi médical et des traitements adaptés."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque des porphyries ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, certains médicaments et des conditions hépatiques."
}
},
{
"@type": "Question",
"name": "L'hérédité joue-t-elle un rôle ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines porphyries sont héréditaires et peuvent être transmises dans les familles."
}
},
{
"@type": "Question",
"name": "Les femmes sont-elles plus à risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines études montrent que les femmes peuvent être plus touchées par certaines porphyries."
}
},
{
"@type": "Question",
"name": "L'alcool augmente-t-il le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la consommation d'alcool peut déclencher des crises chez les personnes prédisposées."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles aggraver la condition ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines infections peuvent exacerber les symptômes des porphyries."
}
}
]
}
]
}
In this cross-sectional analysis of UK Biobank participants, we find no adverse association between self-reported oral health conditions and either glaucoma or elevated intraocular pressures....
Poor oral health may cause inflammation that accelerates the progression of neurodegenerative diseases. We investigated the relationship between oral health and glaucoma....
United Kingdom (UK) Biobank participants....
This is a cross-sectional analysis of participants categorized by self-reported oral health status. Multivariable linear and logistic regression models were employed. Primary analysis examined the ass...
170,815 participants (34.3%) reported current oral health problems, including painful or bleeding gums, toothache, loose teeth, and/or denture wear. 33,059, 33,004, 14,652, and 14,613 participants wer...
Self-reported oral health was not associated with elevated IOP nor increased risk of glaucoma. Future studies should confirm the null association between clinically diagnosed oral health conditions an...
Cell culture is a powerful technique for the investigation of molecular mechanisms fundamental to health and disease in a diverse array of organisms. Cell lines offer several advantages, namely their ...
We examine judgements of bias in distributional outcomes. Such judgements are often based on imbalance in distributional outcomes, namely, the under- or over-representation of a target group relative ...
Aim of this study was to investigate a dose-response relationship, dose-toxicity relationship, progression free survival (PFS) and overall survival (OS) in neuroendocrine tumour liver metastases (NELM...
Single center, retrospective study included patients with NELM that received [...
Twenty-seven treatments in 25 patients were included, with a total of 114 tumours. Median follow-up was 14 months (3 - 82 months). Mean D...
This study confirms the safety and efficacy of [...
We report superconductivity in the full Heusler compound LiPd...
Familial partial lipodystrophy (FPLD) is a heterogenous group of syndromes associated with a high prevalence of cardiometabolic diseases. Prior work has proposed DEXA-derived fat mass ratio (FMR) - de...
The aim of this study is to explore the relationship that people with cancer and their family caregivers develop with symptom management technology during chemotherapy....
A longitudinal and multi-perspective interpretative phenomenological approach was adopted. Data were collected using one-to-one in-depth interviews with people with colorectal cancer using supportive ...
People with cancer and their family caregivers can develop emotional bonds with supportive symptom management technology during cancer treatment. Digital health technology can be experienced as a pers...
The relationship and psychological bonds people with cancer and their family caregivers develop with technology during treatment may be critically important for oncology nurses to be aware of should d...
Prestin is an outer hair cell (OHC) protein responsible for increasing cochlear sensitivity and has been proposed as a biomarker. We aimed to evaluate whether the serum prestin level is related to the...
Ninety subjects were recruited from the patient base at Samarra public hospitals and clinics in Iraq from January to October of 2022. They were divided into three groups equally: a group of healthy pe...
Hearing thresholds were sequentially statistically higher across the three groups. While prestin levels were significantly higher in G1 and G2 than that in G0, there were no differences between the G1...
Our results suggest that in the clinical setting, prestin is sensitive to chronic mild to moderate SNHL (i.e., up to 40-60 dB), not more severe loss. This range is consistent with the added sensitivit...
Patients with chronic kidney disease (CKD) are susceptible to frailty because of a range of nutrition-related factors. While protein restriction is commonly advised to preserve kidney function in pati...
This cross-sectional study enrolled patients with CKD stage 3-5. Frailty and prefrailty were assessed using the Japanese version of the Cardiovascular Health Study (J-CHS) criteria. To estimate dietar...
Ninety-seven individuals with CKD were included in the study, with a median age of 73.0 years (interquartile range: 67.0, 82.0). Among them, 34 were women (35.1%), and the estimated glomerular filtrat...
Reduced protein intake in patients with CKD is associated with frailty and pre-frailty. It is advisable to ensure that patients with CKD who are at risk of frailty consume an adequate amount of protei...
Few studies have investigated specific associations between insomnia and orofacial pain (OFP). The aim of this cross-sectional study was to examine relationships of insomnia with pain, mental health, ...
. OFP diagnosis, demographics, insomnia symptoms, pain intensity, interference, and duration, mental health measures, and number of medical comorbidities were extracted from the medical records of 450...
Compared to patients without insomnia, those with elevated insomnia symptomatology (45.1%) reported higher pain intensity (60.70 ± 20.61 vs 44.15 ± 21.69; p < 0.001) and interference (43.81 ± 29.84 vs...
Insomnia is associated with pain outcomes and should be appropriately managed when treating patients with chronic OFP....